259 related articles for article (PubMed ID: 24343455)
1. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.
Xuan D; Yu Y; Shao L; Wang J; Zhang W; Zou H
Clin Rheumatol; 2014 Apr; 33(4):577-86. PubMed ID: 24343455
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
5. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
6. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
8. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
[TBL] [Abstract][Full Text] [Related]
10. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
Schwaneck EC; Krone M; Kreissl-Kemmer S; Weißbrich B; Weiss J; Tony HP; Gadeholt O; Schmalzing M; Geier A
Clin Rheumatol; 2018 Nov; 37(11):2963-2970. PubMed ID: 30238380
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
12. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis.
Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M
Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453
[TBL] [Abstract][Full Text] [Related]
13. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
[TBL] [Abstract][Full Text] [Related]
14. Safety of Corticosteroid Treatment in Rheumatologic Patients With Markers of Hepatitis B Viral Infection: Pilot Evaluation Study.
Braun-Moscovici Y; Braun M; Saadi T; Markovits D; Nahir MA; Balbir-Gurman A
J Clin Rheumatol; 2016 Oct; 22(7):364-8. PubMed ID: 27660934
[TBL] [Abstract][Full Text] [Related]
15. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
Chiu YM; Lai MS; Chan KA
PLoS One; 2018; 13(4):e0196210. PubMed ID: 29694398
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for losing hepatitis B virus surface antibody in patients with HBV surface antigen negative/surface antibody positive serostatus receiving biologic disease-modifying anti-rheumatic drugs: a nested case-control study.
Hung MH; Tien YC; Chiu YM
Adv Rheumatol; 2021 Apr; 61(1):22. PubMed ID: 33832541
[TBL] [Abstract][Full Text] [Related]
17. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
Su J; Long L; Zou K
Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
Laohapand C; Arromdee E; Tanwandee T
Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases.
Thong BY; Koh ET; Chng HH; Chow WC
Ann Acad Med Singap; 2007 Feb; 36(2):100-5. PubMed ID: 17364075
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
Talotta R; Atzeni F; Sarzi Puttini P
BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
